Online citations, reference lists, and bibliographies.
← Back to Search

Serum Mesothelin For Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-analysis.

Kevin Hollevoet, J. Reitsma, J. Creaney, B. Grigoriu, Bruce W. Robinson, Arnaud Scherpereel, A. Cristaudo, H. Pass, K. Nackaerts, José A. Rodríguez Portal, Joachim Schneider, T. Muley, Francesca Di Serio, P. Baas, M. Tomasetti, Alex J. Rai, J. van Meerbeeck
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. METHODS The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. IPD of 4,491 individuals were collected, including several control groups and 1,026 patients with malignant pleural mesothelioma. Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. RESULTS At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. The resulting area under the ROC curve was 0.77 (95% CI, 0.73 to 0.81). At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% to 40%). CONCLUSION In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.
This paper references
10.1289/ehp.1002285
The Case for a Global Ban on Asbestos
J. LaDou (2010)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1158/1055-9965.EPI-05-0334
Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker
I. Hellstrom (2006)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1097/JTO.0b013e31820db377
Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
K. Hollevoet (2011)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
The cytology of malignant mesothelioma.
D. Whitaker (2000)
10.1016/J.EJCA.2007.08.028
Mesothelin targeted cancer immunotherapy.
R. Hassan (2008)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1016/J.LUNGCAN.2007.08.030
Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
M. M. van den Heuvel (2008)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1016/j.clinbiochem.2009.03.007
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
B. Grigoriu (2009)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1016/S0140-6736(05)66422-7
Refining clinical diagnosis with likelihood ratios
D. Grimes (2005)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1136/bmj.d549
Interpretation of random effects meta-analyses
R. Riley (2011)
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma : evaluation in comparison with mesothelin
岩堀 幸太 (2009)
10.1093/aje/kwn099
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting.
H. Janes (2008)
10.1097/JTO.0b013e3181ec173d
Receiver operating characteristic curve in diagnostic test assessment.
J. Mandrekar (2010)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1378/chest.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1517/17530059.1.1.137
MESOMARK(®) in vitro diagnostic test for mesothelioma.
Zhong-Qian Li (2007)
10.1038/bjc.2011.104
Markers for the non-invasive diagnosis of mesothelioma: a systematic review
S. van der Bij (2011)
10.1016/S1556-0864(15)31535-5
Soluble Mesothelin Related Protein in Mesothelioma
J. Creaney (2006)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1515/CCLM.2007.112
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
F. di Serio (2007)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
Lake RA: Malignant mesothelioma
BW Robinson (2005)
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/J.JCLINEPI.2005.02.022
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews.
J. Reitsma (2005)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1186/1471-2288-3-25
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
P. Whiting (2003)
10.1053/j.semtcvs.2009.07.004
Multimodality strategies in malignant pleural mesothelioma.
W. Weder (2009)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)



This paper is referenced by
10.1179/1351000213Y.0000000064
Mitochondrial targeting of α-tocopheryl succinate enhances its anti-mesothelioma efficacy
J. Kovářová (2014)
10.1016/j.ccm.2012.08.005
The classic pneumoconioses: new epidemiological and laboratory observations.
A. Laney (2012)
10.1016/j.arbres.2014.06.005
Diagnosis and treatment of malignant pleural mesothelioma.
F. Rodríguez Panadero (2015)
10.3389/fonc.2019.00740
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
I. Cavallari (2019)
10.1016/J.CTRC.2015.02.002
Spontaneous regression of malignant pleural mesothelioma: A case report
Jacques Raphael (2015)
10.1016/j.ejso.2018.02.010
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Federica Bruno (2018)
Chronic Inflammation in Malignant Mesothelioma Pathogenesis: Focus on HMGB1 Isoforms and Germline BAP1 Mutations
A. Napolitano (2015)
10.1016/J.EJCDT.2014.08.001
Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions
A. Elgazzar (2014)
10.1201/B16389-23
Noninvasive Early Markers in Lung Cancer
Mukesh Verma (2014)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1007/s00408-012-9445-1
Management of Malignant Pleural Effusion
J. Kastelik (2012)
10.1016/J.REVMED.2014.10.360
Orientation diagnostique et conduite à tenir devant un épanchement pleural
J. Pastre (2015)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1002/cam4.297
Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
T. Sato (2014)
Immunotherapy advances for mesothelioma
Emyr Bakker (2018)
10.18632/oncotarget.17436
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
Long Tian (2017)
10.1007/s12032-012-0422-6
Individual predictors of increased serum mesothelin in asbestos-exposed workers
R. Filiberti (2013)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
10.1016/S0304-5412(14)70874-1
Cáncer de pleura: mesotelioma
Jesus Fernandez Frances (2014)
10.1007/s00408-019-00244-1
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma
Carmina Jiménez-Ramírez (2019)
10.1016/J.EJCDT.2015.04.014
Combined serum and immunohistochemical differentiation between reactive, and malignant mesothelial proliferations
Gehan F. Al mehy (2015)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
10.1016/j.jtho.2018.06.011
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
L. Mutti (2018)
10.1016/j.soc.2012.12.004
Multimodality treatment of pleural mesothelioma.
David D. Shersher (2013)
MALIGNANT PLEURAL MESOTHELIOMA : SPOTLIGHT ON RECENT ADVANCES IN DIAGNOSIS AND TREATMENT
Aline N. Zouk (2017)
10.1007/978-3-030-16884-1_3
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
10.1183/13993003.00919-2017
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
K. Lamote (2017)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.1016/j.lungcan.2013.05.014
The role of epigenetics in malignant pleural mesothelioma.
Fabian Vandermeers (2013)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1016/j.arbres.2016.12.014
Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease.
Carmen Diego Roza (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar